Statement from Reckitt Benckiser concerning Subutex

“Reckitt Benckiser Pharmaceuticals Inc. is discontinuing distribution and sale of Subutex® tablets as we believe that mono product (product containing buprenorphine alone with no naloxone) creates a greater risk of misuse, abuse and diversion, and while other mono product may be available on the market, we are concentrating our efforts around less abusable products in order to protect patients, communities and access to treatment.”